comparemela.com

Page 11 - Amrx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Amneal Pharmaceuticals (AMRX) Maintains Rating Reiterated at 500 com

500.com reiterated their maintains rating on shares of Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) in a research note released on Monday, Benzinga reports. A number of other equities analysts also recently commented on the stock. StockNews.com assumed coverage on shares of Amneal Pharmaceuticals in a research note on Friday, March 17th. They issued a hold […]

Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded to Buy by StockNews com

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. Amneal Pharmaceuticals Stock Performance AMRX traded up $0.10 during trading on Monday, hitting $2.02. 751,600 shares of the stock traded hands, compared to its average volume […]

Amneal Pharmaceuticals (NYSE:AMRX) Shares Gap Up After Earnings Beat

Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating)’s stock price gapped up prior to trading on Monday following a better than expected earnings announcement. The stock had previously closed at $1.92, but opened at $2.00. Amneal Pharmaceuticals shares last traded at $1.94, with a volume of 81,318 shares changing hands. The company reported $0.10 earnings per […]

Amneal Pharmaceuticals (NYSE:AMRX) Releases Quarterly Earnings Results, Beats Expectations By $0 01 EPS

Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) issued its quarterly earnings results on Friday. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.01, Yahoo Finance reports. Amneal Pharmaceuticals had a positive return on equity of 76.11% and a negative net margin of 5.88%. The firm had revenue […]

Brokerages Set Amneal Pharmaceuticals, Inc (NYSE:AMRX) Price Target at $3 75

Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.